Search clinical trials for: Doravirine/Lamivudine/Tenofovir

Total 1494 results

Merck Sharp & Dohme LLC

Completed

Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)

HIV-1 | Central Nervous System
Merck Sharp & Dohme LLC

Completed

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

HIV-1 Infection

United States, Chile, France, United Kingdom
First Affiliated Hospital Xi'an Jiaotong University

Unknown

Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection

Hepatitis B, Chronic

China
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Recruiting

Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

HIV Infections

United States
Professor Francois Venter

Recruiting

ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance (ADORE)

HIV-1-infection

South Africa
Professor Francois Venter

Completed

DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (DORA)

HIV-1-infection

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

HIV Infections

United States, South Africa, Thailand
ANRS, Emerging Infectious Diseases
MSD France

Not yet recruiting

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection (ELDORADO)

HIV-1-infection

Brazil, Cambodia, Cameroon, Côte D'Ivoire, France, Mozambique
Lee's Pharmaceutical Limited

Unknown

A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)

Acquired Thrombotic Thrombocytopenic Purpura

China
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) (DRIVE BEYOND)

HIV-1 Infection
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects

Bacterial Infections

United States
University Hospital, Caen
Merck Sharp & Dohme LLC

Not yet recruiting

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road) (DOR)

Hiv

France
Merck Sharp & Dohme LLC

Completed

Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) (DRIVE-AHEAD)

Human Immunodeficiency Virus (HIV)
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (DRIVE-SHIFT)

HIV-1 Infection
Thomas Benfield

Recruiting

Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil (AVERTAS-2)

HIV Infections | Obesity | Renal Insufficiency | Osteoporosis | Hiv | Weight Gain | HIV Lipodystrophy

Denmark
ViiV Healthcare

Completed

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
Thomas Jefferson University

Completed

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women (IDENTIFY)

Gender Dysphoria | Transgender Women | Transgender Health | Human Immunodeficiency Virus

United States
Rigshospitalet, Denmark
University of Copenhagen

Completed

Backup With Combivir or Single Dose (SD) Truvada in Order to Avoid Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance After SD Nevirapine for the Prevention of Mother-to-child Transmission (PMTCT)

HIV Infections

Tanzania
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Recruiting

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

HIV Infections | Pregnancy Related

United States
University of Colorado, Denver
Gilead Sciences

Completed

Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance

Weight Gain | HIV-1-infection

United States
Makerere University
Massachusetts General Hospital

Completed

Transgender Men and HIV in Uganda: PrEP Uptake and Persistence

PrEP | HIV | Sexually Transmitted Infections | Transgender Men

Uganda
University of North Carolina, Chapel Hill
Janssen Pharmaceuticals

Completed

Evaluating Once Daily Etravirine in Treatment-Naive Adults With HIV Infection

HIV Infections

United States
ViiV Healthcare

Completed

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

HIV Infection

United States
Uijeongbu St. Mary Hospital

Unknown

Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir

Proportion of Patients With a Sustained Virological Response (Serum HBV DNA <20 IU/mL) at Week 48
GlaxoSmithKline

Completed

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV (HEAT)

HIV Infection

United States, Puerto Rico
Gamaleya Research Institute of Epidemiology and...
MSD Pharmaceuticals LLC

Not yet recruiting

HIV A6 Genome In ART Unsuccessful Patients On DOR (HIV-A6-DOR)

Virus-HIV
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)

HIV-1 Infection
Taipei Veterans General Hospital, Taiwan
China Medical University Hospital; Kaohsiung Medical University Chung-Ho Memorial... and other collaborators

Unknown

Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients

Chronic Hepatitis B

Taiwan
Quest Clinical Research
Gilead Sciences

Completed

Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine

HIV-1-infection

United States
Gilead Sciences

Completed

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

HIV Infections

United Kingdom
University of Alabama at Birmingham
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Recruiting

Reducing Vertical Transmission of Hepatitis B in Africa (REVERT-B)

Hepatitis B Infection

United States
Myanmar Oxford Clinical Research Unit
Institute of Tropical Medicine, Belgium; Medical Action Myanmar

Completed

PrEP Among MSM and TG in Myanmar (PrEP)

HIV Infections

Myanmar
Johnson & Johnson Pte Ltd

Terminated

A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (RISE)

Human Immunodeficiency Virus Infections

India
Merck Sharp & Dohme LLC

Completed

A Study Evaluating the Pharmacokinetics of Doravirine (MK-1439) in Participants With Severe Renal Impairment (MK-1439-051)

Renal Impairment
Bristol-Myers Squibb

Terminated

A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection

Chronic Hepatitis B

Germany, Turkey, United States, Poland, Belgium, Italy
St. Luke's-Roosevelt Hospital Center
Gilead Sciences

Completed

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects (TRU)

HIV

United States
University of Washington
National Institute of Allergy and Infectious Diseases (NIAID); Merck Sharp... and other collaborators

Terminated

RESIST-2: 2nd-line ART for HIV-2 Infection (RESIST-2)

HIV-2 Infection

Senegal
Charlotte-Paige Rolle, MD
ViiV Healthcare

Completed

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF (DYAD)

HIV I Infection

United States
University of Colorado, Denver

Completed

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

HIV-1-infection

United States
University of California, San Francisco
Bristol-Myers Squibb

Completed

Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

HIV Infections | Hepatitis B

United States
St Stephens Aids Trust
Mylan Inc.

Completed

SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women

HIV

United Kingdom
ANRS, Emerging Infectious Diseases

Completed

First-Line Treatment for HIV-2 (FIT-2)

HIV-2 Infection

Côte D'Ivoire, Burkina Faso, Senegal, Togo
Gilead Sciences

Completed

Safety and Efficacy Study of Switching From Epzicom to Truvada (SWIFT)

HIV Infection

United States, Puerto Rico, Canada
Merck Sharp & Dohme LLC

Completed

Bioavailability of Doravirine (MK-1439) Experimental Nano Formulations in Healthy Adults (MK-1439-046)

Human Immunodeficiency Virus-1 (HIV-1)
Azienda Ospedaliera Universitaria Senese
Catholic University of the Sacred Heart; Ospedale Policlinico San Martino; Azienda... and other collaborators

Unknown

Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen (DOBINeuro)

HIV-1-infection

Italy
ANRS, Emerging Infectious Diseases
Merck Sharp & Dohme LLC; Ministry of Health, Brazil

Completed

Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis (REFLATE TB2)

Tuberculosis | HIV-1 Infection

France, Vietnam, Brazil, Côte D'Ivoire, Mozambique
Kirby Institute

Completed

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

HIV Infections

Australia
Kaohsiung Veterans General Hospital.

Unknown

Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation (HBSAE)

Chronic HBV With Severe Exacerbation

Taiwan
Yunnan AIDS Care Center

Unknown

Safety and Efficacy of Raltegravir+TDF+3TC in HBV/HIV Co-infected Patients

HIV Infections | HBV Coinfection

China
University of Witwatersrand, South Africa
Bill and Melinda Gates Foundation; ViiV Healthcare

Active, not recruiting

Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa (AXIS)

HIV Infections

South Africa

3

Subscribe